abstract |
In the present invention, a CLD18A2 target chimeric antigen receptor and methods for its preparation and use are disclosed. The extracellular binding domain of the chimeric antigen receptor contains a protein that specifically recognizes CLD18A2, and the immune effector cells modified with the chimeric antigen receptor are useful for the treatment of tumors such as pancreatic cancer and gastric cancer. [Selection figure] None |